Iroko Pharmaceuticals has launched a new corporate headquarters in Philadelphia's Navy Yard Corporate Center, US.
The new facility will support increased workforce as the company moves ahead with five late-stage development programs to commercialize four drug candidates.
The 56,412ft2 facility forms part of the company's long-term growth plan to advance its late-stage pipeline of lower dose submicron non-steroidal anti-inflammatory drugs (NSAIDs) towards commercialization.
The four-story facility is also designed to accommodate nearly 180 employees.
Iroko Pharmaceuticals president and CEO John Vavricka said, "The success of Iroko Pharmaceuticals mirrors the growth and transformation of the historic Philadelphia Navy Yard itself, a place we have called home since founding this company five years ago."
Iroko develops lower dose submicron NSAIDs, using proprietary SoluMatrix technology, designed as a pain reliever at lower doses than existing commercially-available NSAIDs.
Iroko chairman Osagie Imasogie said, "Iroko was built on an ambitious yet simple vision, which is to bring meaningful therapeutic improvements to patients and physicians by utilizing scientific innovation to optimize widely-used and trusted medications."
